HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Regenxbio (NASDAQ:RGNX) and maintained a price target of $38.
June 20, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Regenxbio and maintained a price target of $38, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $38 price target by HC Wainwright & Co. suggests strong confidence in Regenxbio's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100